Prolonged hematological remission by mitoxantrone and interferon ‐ α‐2b in a child with resistant Philadelphia chromosome‐positive chronic myelogenous leukemia

The major problems in chemotherapy are occasional low response rates in patients despite favourable in vitro action, the development of drug resistance and long or short term adverse effects. Therefore, in the past decade efforts have been made to circumvent these problems by combining antineoplastic drugs with biomodulating or cytoprotective agents. Most of the clinically useful drug regimens consist of a cocktail of drugs with different mechanisms of action, and hence different toxicity profiles. Dose-limiting factors in regard to toxicity and therapeutic efficacy predominate, and it is therefore clinically essential to know whether or not a pharmacokinetic drug interaction occurs. The introduction of interferon-alpha (IFNalpha) in chemotherapy is an alternative investigational approach to amplify the cytotoxicity of an antineoplastic drug in order to increase tumour response. Most of the clinical studies reported with IFNalpha provide useful information and identify major pharmacodynamic interactions, but only a few focus on and report potential pharmacokinetic interactions between antineoplastic drugs and IFNalpha in patients. The broad spectrum of antineoplastic drugs whose activity can be enhanced by IFNalpha argues for multiple levels of drug-drug interactions: protein binding (cisplatin), alteration in cellular uptake, modulation of drug target enzymes (dihydropyrimidine hydrogenase) and changes in biotransformation (tretinoin) or excretion. Pharmacokinetic and/or pharmacodynamic interactions may be beneficial (fluorouracil) or sometimes detrimental and coincidental (doxorubicin). This article focuses on observed pharmacokinetic drug interactions between IFNalpha and antineoplastic drugs and discusses possible mechanisms of action.

show abstract

Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-?? and Antineoplastic Drugs

Czejka

Schueller

Kletzl

et al. 1999

BioDrugs

View full text Add to dashboard Cite

show abstract

Clinical and Hematological Remission After a Single Dose of Mitoxantrone in a Child with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Hiçsönmez

Olcay

1997

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Prolonged hematological remission by mitoxantrone and interferon ‐ α‐2b in a child with resistant Philadelphia chromosome‐positive chronic myelogenous leukemia

Cited by 2 publications

References 7 publications

Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-?? and Antineoplastic Drugs

Clinical Significance of Pharmacokinetic Drug Interactions Between Interferon-?? and Antineoplastic Drugs

Clinical and Hematological Remission After a Single Dose of Mitoxantrone in a Child with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Contact Info

Product

Resources

About